Trevi Therapeutics (TRVI) Non Operating Income (2018 - 2025)
Trevi Therapeutics' quarterly Non Operating Income came in at $6.5 million in Q4 2025, up 336.78% year-on-year from $1.5 million in Q4 2024, and up 210.67% quarter-over-quarter from $2.1 million in Q3 2025.
Trevi Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $6.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income rose 336.78% year-over-year to $6.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.9 million (up 797.5% YoY), and the FY2025 full-year result was $6.5 million, up 43466.67% from the prior year.
- Non Operating Income for Q4 2025 stood at $6.5 million, up from $2.1 million in the prior quarter.
- The five-year high for Non Operating Income was $6.5 million in Q4 2025, with the low at -$2.8 million in Q4 2024.
- Average Non Operating Income over 5 years is $662263.2, with a median of $132000.0 recorded in 2022.
- Year-over-year, Non Operating Income plunged 4592.86% in 2021 and soared 19181.82% in 2025.
- Tracing TRVI's Non Operating Income over 5 years: stood at -$253000.0 in 2021, then jumped by 377.47% to $702000.0 in 2022, then soared by 520.23% to $4.4 million in 2023, then sank by 163.25% to -$2.8 million in 2024, then soared by 336.78% to $6.5 million in 2025.
- The last three Non Operating Income figures came in at $6.5 million (Q4 2025), $2.1 million (Q3 2025), and -$7000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.52 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | -7,000.00 |
| Dec 31, 2024 | -2.75 Mn |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 929,000.00 |
| Mar 31, 2024 | 996,000.00 |
| Dec 31, 2023 | 4.35 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Dec 31, 2022 | 702,000.00 |
| Sep 30, 2022 | 132,000.00 |
| Jun 30, 2022 | -236,000.00 |
| Mar 31, 2022 | -309,000.00 |
| Dec 31, 2021 | -253,000.00 |
| Sep 30, 2021 | -306,000.00 |
| Jun 30, 2021 | -629,000.00 |
| Mar 31, 2021 | -297,000.00 |
| Dec 31, 2020 | -313,000.00 |
| Sep 30, 2020 | -145,000.00 |
| Jun 30, 2020 | 14,000.00 |
| Mar 31, 2020 | 157,000.00 |
| Dec 31, 2019 | 225,000.00 |
| Sep 30, 2019 | 280,000.00 |
| Jun 30, 2019 | 66,000.00 |
| Mar 31, 2019 | 6,000.00 |
| Dec 31, 2018 | -102,000.00 |
| Sep 30, 2018 | -722,000.00 |
| Jun 30, 2018 | -503,000.00 |
| Mar 31, 2018 | -934,000.00 |